Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) kicked off on Friday, down -4.85% from the previous trading day, before settling in for the closing price of $9.07. Over the past 52 weeks, AUPH has traded in a range of $5.20-$10.67.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 1365.00%. With a float of $119.37 million, this company’s outstanding shares have now reached $137.75 million.
In an organization with 130 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 88.24%, operating margin of 12.61%, and the pretax margin is 16.91%.
Aurinia Pharmaceuticals Inc (AUPH) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Aurinia Pharmaceuticals Inc is 11.64%, while institutional ownership is 45.05%. The most recent insider transaction that took place on Mar 07 ’25, was worth 68,350. In this transaction Chief Medical Officer of this company sold 8,305 shares at a rate of $8.23, taking the stock ownership to the 153,484 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Chief Executive Officer sold 195,593 for $8.00, making the entire transaction worth $1,564,744. This insider now owns 1,953,892 shares in total.
Aurinia Pharmaceuticals Inc (AUPH) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 1365.00% per share during the next fiscal year.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Trading Performance Indicators
Take a look at Aurinia Pharmaceuticals Inc’s (AUPH) current performance indicators. Last quarter, stock had a quick ratio of 5.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.71. Likewise, its price to free cash flow for the trailing twelve months is 18.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.28, a number that is poised to hit 0.14 in the next quarter and is forecasted to reach 0.76 in one year’s time.
Technical Analysis of Aurinia Pharmaceuticals Inc (AUPH)
Let’s dig in a bit further. During the last 5-days, its volume was 1.82 million. That was better than the volume of 1.47 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 80.89%.
During the past 100 days, Aurinia Pharmaceuticals Inc’s (AUPH) raw stochastic average was set at 78.79%, which indicates a significant increase from 70.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.44 in the past 14 days, which was higher than the 0.32 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.16, while its 200-day Moving Average is $8.10. However, in the short run, Aurinia Pharmaceuticals Inc’s stock first resistance to watch stands at $8.97. Second resistance stands at $9.31. The third major resistance level sits at $9.49. If the price goes on to break the first support level at $8.45, it is likely to go to the next support level at $8.27. The third support level lies at $7.93 if the price breaches the second support level.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Key Stats
The company with the Market Capitalisation of 1.17 billion has total of 135,104K Shares Outstanding. Its annual sales at the moment are 235,130 K in contrast with the sum of 5,750 K annual income. Company’s last quarter sales were recorded 62,470 K and last quarter income was 23,340 K.
